US · LGND · BIOTECHNOLOGY
Ligand Pharmaceuticals Incorporated (LGND) intrinsic value and stock valuation
$286.85as of 2026-11-21 · Mkt cap 5.88B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ligand Pharmaceuticals Incorporated DCF and intrinsic value
InvestorsCraft values LGND with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from LGND’s statements →
Ligand Pharmaceuticals Incorporated Graham Number
Graham Number: $87.27d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Praxis Precision Medicines, Inc. (PRAX) $300.43
- Crinetics Pharmaceuticals, Inc. (CRNX) $84.95
- Belite Bio, Inc (BLTE) $127.38
- Mirum Pharmaceuticals, Inc. (MIRM) $96.13
- ACADIA Pharmaceuticals Inc. (ACAD) $17.11
- Dyne Therapeutics, Inc. (DYN) $15.50
- Viking Therapeutics, Inc. (VKTX) $24.77
- NewAmsterdam Pharma Company N.V. (NAMS) $18.41
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.3M | $241.5M |
| Operating income | $47.2M | -$-22.61M | $11.9M | $3.04M | $103.9M |
| Net income | $124.5M | -$-4.03M | $52.2M | -$-33.36M | $57.1M |
| EPSd | $6.13M | -$-220.34K | $2.94M | -$-1.98M | $3.31M |
| Operating cash flow | $49.4M | $97.1M | $49.6M | $137.9M | $78.8M |
| Capital expenditure | -$-450K | -$-19.64M | -$-53.85M | -$-17.92M | -$-8.76M |
| Free cash flow | $48.9M | $77.4M | -$-4.27M | $119.9M | $70M |
| Total assets | $1.56B | $941.8M | $787.2M | $762.7M | $1.3B |
| Total debt | $451.5M | $7.11M | $6.17M | $87.8M | $324.4M |
| Net debt | $276.6M | -$-65.2M | -$-16.79M | $42.7M | $304.9M |
| Total equity | $1.02B | $830.4M | $700.9M | $597.5M | $821.2M |
| Cash and short-term investments | $733.5M | $256.2M | $170.3M | $211.9M | $341.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.3M | $241.5M |
| Cost of revenue | $6.59M | $11.1M | $35.1M | $52.8M | $62.2M |
| Gross profit | $261.5M | $156.1M | $96.3M | $143.4M | $179.4M |
| Research and development expenses | $81.2M | $21.4M | $24.5M | $36.1M | $32.1M |
| Selling, general and administrative expenses | $92.5M | $78.7M | $52.8M | $70.1M | $46.8M |
| Other expenses | $40.7M | $78.6M | $7M | $34.2M | -$-3.38M |
| Operating expenses | $214.3M | $178.7M | $84.3M | $140.4M | $75.5M |
| Cost and expenses | $220.9M | $189.7M | $119.4M | $193.2M | $137.7M |
| Interest income | $13.7M | $8.05M | $7.71M | $2.05M | $890K |
| Interest expense | $4.71M | $3.04M | $660K | $1.8M | $19.6M |
| Depreciation and amortization | $33.8M | $35.2M | $36.5M | $43.4M | $51M |
| Ebitda | $192.7M | $40.8M | $100.8M | $81.2M | $142.8M |
| Operating income | $47.2M | -$-22.61M | $11.9M | $3.04M | $103.9M |
| Total other income/expenses, net | $111.8M | $25.1M | $51.7M | $33M | -$-31.65M |
| Income before tax | $159M | $2.52M | $63.7M | $36M | $72.2M |
| Income tax expense | $34.5M | $6.55M | $9.84M | $41.2M | -$-4.15M |
| Net income | $124.5M | -$-4.03M | $52.2M | -$-33.36M | $57.1M |
| Weighted average shares outstanding | $19.3M | $18.3M | $17.3M | $16.9M | $16.6M |
| Weighted average diluted shares outstanding | $20.3M | $18.3M | $17.8M | $16.9M | $17.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $733.5M | $256.2M | $170.3M | $211.9M | $341.1M |
| Net receivables | $61.1M | $42.5M | $39.3M | $35M | $91.7M |
| Inventory | $9.13M | $14.1M | $24M | $13.3M | $27.3M |
| Total current assets | $832.3M | $331.6M | $237.4M | $263.6M | $464.8M |
| Property, plant and equipment, net | $10.8M | $24.8M | $25.1M | $27.5M | $32.6M |
| Goodwill and intangible assets | $523.9M | $371.9M | $403M | $458.3M | $492.5M |
| Long-term investments | $183.6M | $10.9M | $111.6M | $3M | $0.00 |
| Total non-current assets | $728.4M | $610.2M | $549.8M | $499.1M | $832.8M |
| Total assets | $1.56B | $941.8M | $787.2M | $762.7M | $1.3B |
| Accounts payable | $3.24M | $5.23M | $2.43M | $5.31M | $8.4M |
| Short-term debt | $1.09M | $1.29M | $410K | $77.4M | $1.41M |
| Deferred revenue | $620K | $1.9M | $1.84M | $980K | $650K |
| Total current liabilities | $37.5M | $37.1M | $16.8M | $98.8M | $41.7M |
| Long-term debt | $450.4M | $5.82M | $5.75M | $10.3M | $323M |
| Deferred revenue, non-current | $0.00 | $0.00 | $15.1M | $40K | $0.00 |
| Total non-current liabilities | $506M | $74.2M | $69.5M | $66.4M | $434.8M |
| Capital lease obligations | $5.3M | $7.11M | $6.17M | $11.1M | $3.67M |
| Total liabilities | $543.4M | $111.3M | $86.3M | $165.2M | $476.4M |
| Common stock | $20K | $20K | $20K | $20K | $20K |
| Retained earnings | $608.1M | $499M | $503M | $450.9M | $449.1M |
| Accumulated other comprehensive income (loss) | $8.46M | -$-5.94M | -$-820K | -$-980K | -$-920K |
| Total equity | $1.02B | $830.4M | $700.9M | $597.5M | $821.2M |
| Total investments | $742.2M | $194.8M | $259M | $169.9M | $321.6M |
| Total debt | $451.5M | $7.11M | $6.17M | $87.8M | $324.4M |
| Net debt | $276.6M | -$-65.2M | -$-16.79M | $42.7M | $304.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $124.5M | -$-4.03M | $52.2M | -$-33.36M | $57.1M |
| Depreciation and amortization | $35.7M | $35.2M | $36.5M | $51.4M | $51M |
| Stock-based compensation | $0.00 | $41.1M | $25.7M | $60.3M | $38.8M |
| Change in working capital | -$-12.66M | $19.4M | -$-34.4M | $65.7M | -$-52.16M |
| Accounts receivable | -$-21.74M | -$-6.46M | -$-2.6M | $55.3M | -$-28.62M |
| Inventory | $4.99M | $9.62M | -$-10.87M | $12.1M | -$-430K |
| Accounts payable | $5.88M | $0.00 | -$-4.7M | -$-3.34M | -$-1.17M |
| Net cash provided by operating activities | $49.4M | $97.1M | $49.6M | $137.9M | $78.8M |
| Investments in property, plant and equipment | -$-11.31M | -$-1.82M | -$-3.52M | -$-17.92M | -$-8.76M |
| Acquisitions, net | -$-8.09M | -$-172.19M | -$-25.65M | -$-750K | $490K |
| Net cash used for investing activities | -$-377.32M | -$-143.66M | -$-11.68M | $163.6M | $30.5M |
| Common stock issued | $114.9M | $37.1M | $22.5M | $3.23M | $33.8M |
| Common stock repurchased | -$-15M | $0.00 | $0.00 | $0.00 | -$-18.45M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $428.2M | $97.1M | -$-59.95M | -$-275.99M | -$-137.76M |
| Net change in cash | $102.6M | $49.4M | -$-22.05M | $25.5M | -$-28.44M |
| Cash at end of period | $174.9M | $72.3M | $23M | $45M | $19.5M |
| Operating cash flow | $49.4M | $97.1M | $49.6M | $137.9M | $78.8M |
| Capital expenditure | -$-450K | -$-19.64M | -$-53.85M | -$-17.92M | -$-8.76M |
| Free cash flow | $48.9M | $77.4M | -$-4.27M | $119.9M | $70M |
Line items
Line items
Line items
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
- CEO
- Todd C. Davis
- Employees
- 47
- Beta
- 1.07
Included in
Explore
Frequently asked questions
What is the intrinsic value of Ligand Pharmaceuticals Incorporated (LGND)?
Ligand Pharmaceuticals Incorporated (LGND) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is LGND undervalued?
LGND trades at a price of $286.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.